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systematic review of randomized-comparative clinical trials was performed to deter-
mine the effects and risks associated with the degree of hemoglobin/hematocrit (Hgb/
Hct) level variability outside the recommended range. Diagnostic algorithm and guides 
treatment adaptation were built out of a panel of experts. Resource use and costs data 
were obtained from the Instituto Mexicano del Seguro Social (IMSS). The costs and 
effectiveness were discounted annually at 3%. The threshold to deﬁne a therapy as 
cost-effective was ﬁxed at USD$25,020.00 (least than three times Mexican GDP per 
capita) following the recommendations of WHO’s Commission on Macroeconomics 
and Health. RESULTS: The clinical success rate (patients within 11–12.5 Hbg/dl 
levels) when using C.E.R.A. vs EPO-alpha showed signiﬁcant difference (86.79% 
[95% CI, 84.70%–88.88%] vs 50.48% [95% CI, 47.38%–53.58%] respectively, 
p  0.0001). The treatment care cost per year for C.E.R.A. was US$2,776.13 
(95%CI,US$2,740.9–US$2,811.43) vs US$2,907.88 (95%CI,US$2,883.27–US$2,932.47) 
for EPO-Beta, (p  0.0001); and the hospitalization cost USD$7,089.74 vs 
US$11,255.09 for each one. C.E.R.A. therapy reduces the cost of RA treatment in 
CKD at a 4.53% compared to EPO-alpha therapy and reduced in 37% the hospital 
stay due to Hgb/Hct levels variation. The Cost-effectiveness plane indicates that 
C.E.R.A. is a highly cost-effective therapy; with a probability of 0.60 to be cost saving 
and 0.99 of probability of being cost effective at a USD$4,450 threshold (less than 
one Mexican PIB per capita). CONCLUSIONS: This results show that the use of 
C.E.R.A. for the treatment of RA in patients with CKD is cost-effective.
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OBJECTIVES: The addition of rituximab to cyclophosphamide, vincristine and pred-   
nisolone (R-CVP) signiﬁcantly improved time-to-progression by 17 months in patients         
with previously untreated advanced follicular lymphoma (Marcus et al, 2008). Based      
on these results, we evaluated the clinical outcomes and cost-effectiveness of R-CVP 
versus CVP alone from the perspective of the Romanian National Health Insurance 
House and Ministry of Health. METHODS: A Markov model with a 10-year time 
horizon was developed based on the randomized controlled trial reported by Marcus 
et al. (2008). Rates of disease progression were derived from the PFS Kaplan-Meier 
curves, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group 
database and Romanian age-speciﬁc mortality tables. The duration of the treatment 
effect of rituximab was conservatively applied for the period of clinical trial follow-up 
(90 months) (hazard ratio  0.468). Direct costs included: drug acquisition costs 
(maximum price from Romanian drugs list 2008), hospitalization costs taken from 
NSPHHSM and NHIH (2008) and calculated based on the tariff per chemotherapy 
administration episode, and post-treatment surveillance costs. Costs were discounted 
by 6.0% p.a. RESULTS: This analysis showed that for each FL treatment where R-
CVP is used instead of CVP, the average beneﬁt to the patient would be an additional 
0.983 life years gained (LYG), and 0.931 years when quality-adjusted (QALY). Drug 
acquisition costs were higher with rituximab, however, this was partially offset by 
lower costs for progression. When R-CVP is compared to CVP alone, the incremental 
cost per LYG or QALY gained was calculated as a7155 and a7557, respectively. 
Sensitivity analyses indicated these results were sensitive to the time horizon (longer 
the time horizon, lower the cost per QALY gained) and that the model was robust. 
CONCLUSIONS: This study conﬁrms the long-term clinical and economic beneﬁts of 
adding rituximab to CVP in patients with FL in Romania.
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OBJECTIVES: The rising incidence of invasive fungal infections (IFI), especially inva-
sive aspergillosis, compromises therapeutic outcomes in haematologic cancer patients 
and in transplant recipients.The aim of our analysis was to determine the cost-
 effectiveness of prophylaxis with posaconazole in comparison with standard azole 
therapy (ﬂuconazole or itraconazole) for risk haematology patients in Czech Republic. 
METHODS: The decision-tree economic model was developed for patients with acute 
myelogenous leukemia (AML). The rates of IFI, IFI-related mortality, overall mortality 
and treatment duration were obtained from randomised controlled trials.The cost of 
drugs and IFI hospitalisation was obtained from panel of experts. The model estimates 
total costs, numbers of IFIs, and life-years gained (LYG) per patient in each prophy-
laxis group. Cost and health effects were discounted at 3%. RESULTS: In comparison 
with ﬂuconazole/itraconazole prophylaxis, posaconazole prophylaxis was associated 
with signiﬁcant reduction in the rates of IFI in AML patients, lower IFI-related deaths 
and increased life years. Accumulated cost to the Czech health care system per patient 
receiving the posaconazole regimen was a2770 compared to a2090 for the ﬂucon-
azole/itraconazole regimen. This results in an incremental cost of a680 per patient. 
Incremental life-years saved were 0.016 per patient. The corresponding incremental 
cost effectiveness ratio (ICER) is a42,122 per LYG. Probabilistic sensitivity analysis 
tested numerous assumptions about the model cost and efﬁcacy parameters and found 
that the results were robust to most changes. CONCLUSIONS: In addition to the 
proven efﬁcacy, posaconazole appeared to be cost-effective relative to ﬂuconazole/itra-
conazole in the prophylaxis of IFIs among patients with AML in the settings of Czech 
Republic health care.
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BACKGROUND: Iron deﬁciency and anaemia is common in patients with chronic          
diseases, e.g. chronic kidney disease (CKD), cancer, inﬂammatory bowel disease (IBD), 
and congestive heart failure (CHF) and in connection with large blood losses. One 
appropriate treatment options is intravenous (IV) iron. In Sweden, the Dental and 
Pharmaceutical Beneﬁts Agency, TLV, decides if a medicine should be included in the 
pharmaceutical beneﬁts scheme. TLV makes decisions regarding new products and 
reviews all pharmaceuticals given reimbursement status before 2002. There are three 
IV iron products in Sweden; Ferinject (ferric carboxymaltose), approved for reimburse-     
ment in 2008, and two products approved before 2002: Venofer (iron sucrose) and 
Cosmofer (iron dextran). OBJECTIVES: To present health economic analyses of 
treatment with intravenous iron compared to relevant treatment options in different 
patient populations, i.e. EPO and IV iron vs. EPO and oral iron in CKD, EPO and 
IV iron vs. EPO without iron in cancer, IV Iron vs. no iron in CHF, and IV iron vs. 
oral iron in post-partum and IBD. METHODS: Incremental costs and effects (ICER) 
of IV iron therapy are estimated by comparing relevant treatment alternatives in dif-
ferent patient groups. In CKD, cancer and IBD, model simulations are used. In post-
partum and CHF, a piggyback approach is used. RESULTS: In patients with cancer 
and CKD in dialysis, treatment with IV iron and EPO is found to dominate treatment 
with EPO alone. In IBD patients, intolerant to oral iron, a treatment switch to IV iron 
generated a cost per QALY of a32,377. The ICER for post-partum and CHF patients 
given IV iron compared to oral iron is estimated at a22,280 and a13,850, respectively. 
CONCLUSIONS: The ICER of IV iron treatment compared to relevant alternatives 
is modest for IBD, post-partum and CHF patients and IV iron is dominant for patients 
with haematological cancer and CKD.
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OBJECTIVES: To evaluate the effectiveness and economic consequences of 
treating anemia with original erythropoietic agents in patients with chronic kidney 
disease (CKD) on dialysis and not yet on dialysis. METHODS: The study is a cost-
effectiveness and a cost-minimization analysis based on clinical studies derived from 
the systematic literature search covered Medline and the Cochrane Library. To deter-
mine the economic beneﬁt of using recombinant human erythropoietin (rEPO) agents 
in patients with CKD not on dialysis the comparison between rEPO-A and control 
group were conducted. The cost of rEPO-A, haemodialysis sessions, total days of 
hospitalization, the frequency and the cost of treatment of myocardial infarction were 
taken into account. Cost-minimization analysis were conducted among original eryth-
ropoietic agents (rEPO-A, rEPO-B and Darbepoetin-A (DARB) to determine the one 
who provides the most cost savings in treatment of anemia in patients with CKD on 
dialysis and not on dialysis. RESULTS: This pharmocoeconomic study suggests that 
rEPO-A therapy before dialysis may have a beneﬁcial impact on delaying progression 
to dialysis, reducing hospitalization time and the frequency of cardio-vascular com-
plications. The mean cost savings following the use of rEPO-A before dialysis were 
RUR471,834 (a10,782.3 for June 2009) per patient per year in comparison with 
control group. According to pharmacoeconomic evaluation the application of rEPO-A 
for treatment anemia leads to considerable cost savings in patients with CKD not on 
dialysis (RUR43,761(a1000) per patient per year more than DARB) and in patients 
with CKD on dialysis (RUR83,957(a1918.6) per patient per year more than rEPO-B 
and RUR66,769(a1525.8) per patient per year more than DARB). CONCLUSIONS: 
Correction of anemia with rEPO-A may reduce the utilization of health care resources 
and may lead to improved clinical and economic outcomes.
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OBJECTIVES: Intravenous immunoglobulin (IVIG )has demonstrated improvement 
in chronic inﬂammatory demyelinating polyneuropathy (CIDP) patients in placebo    
contolled trials. However, IVIG is also much more expensive than alternative treat-
ments such as corticosteroids. The objective of the paper is to evaluate, from a Cana-
dian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment 
of CIDP. METHODS: A markov model was used to evaluate the expected costs and 
QALYs for over 5 years for two treatments for CIDP 1) IVIG, and 2) corticosteroids. 
Patients in the IVIG treatment arm could respod or not respond respond or not 
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respond to treatment in the initial 12 weem model cycle. Patients could relapse or 
continue to respond wto treatment in subsequent cycles. Based on pooled efﬁcacy data 
the initial reponse probability for IVIG used in the model was 0.47(95% C.I. 0.36, 
0.58). Based on a published study, the 12 week proability of relaspe used in the model 
was 0.06 (95% C.I. 0.02,0.14). Non-responding IVIG patients were assumed to be 
switched to corticosteroids. Patients on corticosteroids were at risk of a number of 
adverse events (fracture, diabetes, glaucoma, cataract, serious infection) each cycle. 
RESULTS: Over the 5 year time horizon the model estimated the incrmetnal costs and 
QALYs of IVIG treatment compared to corticosteroid treatment to be $105,356 and 
0.188 repsectively. The incremental cost per QALY of IVIG was estaimated to be 
$551,031. The cost per QALY of IVIG was very sensitive to the assumption on fre-
quency and dosing of maintenance IVIG treatment. CONCLUSIONS: Based on 
common willingness to pay thresholds, IVIG might not be perceived as a cost effective 
treatment for CIDP.
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OBJECTIVES: Conduct an economic evaluation comparing treatment costs between 
5% and 10% Intravenous Immunoglobulin (IVIG) preparations. METHODS: A cost-
minimization analysis (CMA) was performed to compare treatment costs between ﬁve 
5% (including one lyophilized product) and one 10% IVIG preparations, as there are 
no differences in outcomes achieved between different IVIG preparations. The CMA 
was done using a societal perspective and cost included both health care costs as well 
as caregiver costs. More speciﬁcally, the following costs were considered in the model: 
drug costs, facility costs, pharmacy and nursing costs and productivity costs. Other 
data included in the model were obtained from the products’ prescribing information. 
One adult patient (65 kg) and one pediatric patient (25 kg) receiving a dose of 0.4 g/kg 
were modeled. RESULTS: Even though equal cost per gram was assumed across all 
the IVIG products considered in the model, total drug cost was higher for one of the 
5% product because of the limited choice in vial sizes for this particular product. Only 
the lyophilized product incurred pharmacy costs for reconstitution ($15.0). Infusion 
time was shortened by 51 minutes with the 10% product (2.0 h compared to the 5% 
products (2.9 h), saving approximately $21.4 per infusion. For the adult patient, 
nursing costs were higher for the 5% products as more vials were required during the 
infusion (4 to 5 vials for 5% vs. 3 for 10%). On average, the use of a 10% preparation 
saved $65.2 per dose for the adult patient and $32.7 per dose for the pediatric patient. 
Assuming a dosing frequency of 3 weeks, yearly savings could range between $522.2 
and $3.072.2 in adults and $486.8 and $831.6 in children. CONCLUSIONS: The 
availability of a 10% IVIG preparation could generate substantial savings compared 
to 5% preparations.
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OBJECTIVES: Thalidomide is an immonumodulatory drug that has been shown in a 
phase III clinical trial to be effective when used in combination with melphalan and 
prednisone (MPT) in patients newly diagnosed with multiple myeloma who are unable 
to undergo stem cell transplant (SCT) or high-dose chemotherapy (HDC). As part of 
an application to the Pharmaceutical Beneﬁts Advisory Committee (PBAC) in Australia 
we assessed whether such use is cost-effective when compared with MP alone, the 
current standard of care. METHODS: Data on the comparative efﬁcacy of MPT versus 
MP alone were sourced from a completed international phase III study. The results 
from that study showed a statistically signiﬁcant difference in median survival of 1.53 
years (p  0.0006) in favour of MPT. We applied a digitising program to the published 
Kaplan-Meier survival curves in order to estimate the mean survival (area under the 
curve) and extrapolate the results to a lifetime horizon. These data were incorporated 
into a cost-effectiveness analysis taking the perspective of the Australian health care 
system. Outcomes were assessed as quality adjusted life years gained (QALYG), based 
on applying published utility values to the extrapolated survival data. The costs of the 
primary drug therapies (MPT or MP), associated medical services, and the treatment 
of thalidomide related adverse events were all included. Costs and beneﬁts were dis-
counted at 5% per annum, and costs were stated in A$ at 2008 prices. RESULTS: 
The modelled analysis estimated an incremental gain in average survival of 1.47 years. 
This translated into 1.14 QALYGs once the utility values were applied. The associated 
average incremental cost was AUS$23,953. The resulting cost per QALYG was 
A$20,998. CONCLUSIONS: This analysis resulted in a positive recommendation 
from the PBAC to fund thalidomide for the treatment of patients newly diagnosed 
with multiple myeloma.
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OBJECTIVES: This study assesses the cost-effectiveness of Intradiscal electrothermal 
therapy (IDET) relative to femoral ring allografts (FRA), a form of spinal fusion, for 
discogenic back pain. Spinal fusion is an established surgical treatment; IDET is less 
invasive and potentially less costly. McKenna (2005) reported an RCT comparing 
FRA and titanium cage (TC). Based on this trial, Freeman (2007) demonstrated the 
relative cost-effectiveness of FRA. The present study used the same FRA cohort for 
evaluating the cost-effectiveness of IDET vs. FRA. METHODS: Patient-level data on 
resource use up to 24 months and SF-36 (measured pre-operatively and at 6, 12, 24 
months) were available for all 37 FRA patients of McKenna (2005) trial. Comparable 
data were collected prospectively on 85 patients treated with IDET at Queen’s Medical 
Centre, Nottingham. Data variables were matched between the two patient groups. 
Utility scores were produced from SF-36 by using Brazier (2004) algorithm. Differen-
tial costs and utilities, together with 95% conﬁdence intervals, were estimated using 
bias corrected and accelerated bootstrapping. RESULTS: There were no signiﬁcant 
differences between the groups in age, gender or SF-36 domain scores, except physical 
function (p  0.004) and mental health (p  0.021), both lower in the FRA group. 
Baseline utility scores were lower in the FRA group (0.48 vs. 0.52, p  0.03).On the 
central assumptions, the expected cost per patient was lower with IDET by £3713 
(95% CI -£2684 to -£4742). The differential QALYs of IDET vs. FRA (adjusted for 
preoperative utilities) were 0.03 (95% CI -0.07 to 0.12). At a willingness-to-pay 
(WTP) threshold of £20,000 per QALY, the net health beneﬁt (NHB) of IDET was 
0.21 and the probability of IDET being cost-effective was 1. If the WTP threshold 
was £30 K/QALY, the NHB was 0.15 (probability cost-effective  0.997). CONCLU-
SIONS: IDET offers a cost-effective alternative to spinal fusion. IDET has the advan-
tage that it is less invasive and can be performed as a day-case procedure.
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OBJECTIVES: . To evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve 
gastrectomy and gastric banding) versus ordinary treatment in health care. METHODS:  
Analysis was done from health care providers’ perspective using a Markov cycle tree 
and a time horizon of ten years. Events during the ﬁrst year, including mortality and 
primary complications resulting in reoperation, were modelled in a decision tree. Then 
the patient cohort moves into a state transition model including four states: alive (no 
reoperation or abdominoplasty), reoperation, abdominoplasty, and death. The param-
eter values were taken from a large representative population survey measuring health-
related quality of life (HRQoL) and health service use, as well as from registers and 
literature. When necessary, expert opinions were used. Different types of sensitivity 
analysis were conducted. RESULTS: . In CUA bariatric surgery dominated strongly 
the ordinary treatment. The mean cost was a31,800 and a44,800 and the mean 
number of QALYs 7.05 and 6.51 for bariatric surgery and ordinary treatment, respec-
tively. Uncertainty around the parameter values was tested comprehensively in sensi-
tivity analyses and the results were robust. CONCLUSIONS: The model takes into 
account all the major events. Strengths of the model include the actual cost data on 
bariatric surgery and inclusion of abdominoplasty, which seems to be neglected in 
previous analyses. Also, a unique set of data on mean health care costs and HRQoL 
for both alternatives was available. The time horizon is rather short and may under-
estimate the effectiveness of bariatric surgery, but it is based on available follow-up 
data.
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OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-
PCA) processes in postoperative pain management in patients in clinical practice that 
has undergone surgery at the Uppsala University Hospital, Sweden. METHODS: 
A model was designed and visualized via swimlane notation. Sub process levels 
were deﬁned as “education”, “purchasing/depreciation/maintenance”, “procure-
ment”, “supply”, “application” and “disposal”. Based on these, data was collected 
by two research methods, interviews and measurement forms including patient and 
staff satisfaction questionnaires. RESULTS: Ten members of hospital personnel with 
different responsibilities were interviewed to deﬁne the roles and activities involved in 
the entire IV-PCA process. Ten different roles were deﬁned with 149 different activi-
ties. The involved roles and the duration of each activity in the sub process levels 
“supply”, “application” and “disposal” were measured from 85 consecutive patients 
with 13 different surgery types. The average duration of IV-PCA use per patient was 
